Source: Fierce Biotech Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline. Buying Chimerix will give Jazz control of the brain cancer drug candidate dordaviprone. The FDA is set to decide whether…...
FDA blesses atopic dermatitis label expansions for Organon’s Vtama, Galderma’s Nemluvio
Source: FiercePharma The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD). Both products now will be available to a significantly larger patient population as roughly 26 million in the U.S. have the disorder, which is also known as eczema. Organon’s…...
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Source: FiercePharma With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close…...
Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Source: Fierce Biotech Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The acquisition, announced Tuesday, would give Incyte ownership over two budding immunology and inflammation candidates, led by EP262, in development for a handful of inflammatory skin conditions. The second asset,…...
LEO Pharma to Acquire Timber Pharmaceuticals
Source: Dermatology Times LEO Pharma announced today its acquisition of Timber Pharmaceuticals, a transaction valued at $36 million.1 Timber Pharmaceuticals has been evaluating the safety and efficacy of its breakthrough therapy, TMB-001, for the treatment of congenital ichthyosis (CI). TMB-001, a topical isotretinoin formulation, was granted Fast Track Designation in April 2022 and Breakthrough Therapy…...
Rick Beck – Founding Recruiter on Forbes.jobs
Meet Rick Beck, a highly respected executive recruiter with a passion for connecting top talent with leading companies in the pharmaceutical, medical device, and biotechnology industries. With a nationwide reach, Rick and his team use a unique 48-point assessment process to ensure the perfect match between candidate and company. From contract sales…...
L’Oreal to acquire skinbetter science
Clichy, September 23, 2022 – L’Oréal signed an agreement to acquire Skinbetter Science, a physician-dispensed American skincare brand backed by cutting-edge, dermatological science, combining patented efficacious ingredients with luxurious sensorial textures. Skinbetter Science was co-founded in 2016 by pharmaceutical industry professionals, Jonah Shacknai, Justin Smith and Seth Rodner, and has since become one…...
EPI Health Announces Acquisition by Novan, Inc. to Create Fully Integrated Specialty Dermatology Company
Source: EPI Health The EP Group (privately held parent company of EPI Health, Inc.) today announced the acquisition of EPI Health, LLC (“EPI Health”) by Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN). Novan will host a conference call and webcast, today, March 11, 2022, at 8:30 a.m. ET (details…...
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
Source: GlobeNewswire Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that the company entered into a definitive agreement with VYNE Therapeutics, Inc. (“VYNE”) to acquire its Molecule Stabilizing Technology…...
Journey Medical Corporation Announces Launch of its Initial Public Offering
Source: GlobesNewswire Journey Medical Corporation (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has launched an initial public offering of 3,200,000 shares…...